Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

terminated133%
completed133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

NCT06860971
terminatedphase_1

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

NCT05011019
completedphase_1

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

NCT06278493

Clinical Trials (3)

Showing 3 of 3 trials
NCT06860971Phase 3

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

Recruiting
NCT05011019Phase 1

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Terminated
NCT06278493Phase 1

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3